Published in An Bras Dermatol on February 01, 2016
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol (2013) 4.26
Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89
Melanoma epidemiology and trends. Clin Dermatol (2008) 2.57
New drugs in melanoma: it's a whole new world. Eur J Cancer (2011) 1.88
Cutaneous melanoma. Lancet (2013) 1.73
Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol (2010) 1.15
Cutaneous melanoma: a 30-year-long epidemiological study conducted in a city in southern Brazil, from 1980-2009. An Bras Dermatol (2011) 1.09
To what extent are current guidelines for cutaneous melanoma follow up based on scientific evidence? Int J Clin Pract (2014) 0.91
Evidence-based clinical practice guidelines on the use of sentinel lymph node biopsy in melanoma. Am Soc Clin Oncol Educ Book (2013) 0.90
Positron emission tomography in the follow-up of cutaneous malignant melanoma patients: a systematic review. Am J Nucl Med Mol Imaging (2013) 0.86
Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy. PLoS One (2013) 0.83
Melanoma metastasis to the gastric mucosa preceded by guillain-barré as a paraneoplastic syndrome. Gastrointest Cancer Res (2013) 0.78
Approaches to regional nodes in patients with melanoma. J Clin Oncol (2014) 0.78